Serum levels of miR-628-3p and miR-628-5p during the early pregnancy are increased in women who subsequently develop preeclampsia.


Journal

Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 01 10 2018
revised: 06 03 2019
accepted: 28 03 2019
entrez: 7 5 2019
pubmed: 6 5 2019
medline: 4 12 2019
Statut: ppublish

Résumé

Preeclampsia pathogenesis involves imbalances of oxidative stress networks including the heat shock protein (HSP) pathway. Micro-RNAs regulate gene networks associated with preeclampsia. Hsp90 and Runx2 are transcriptional targets of miR-628-3p. Considering that potential participation of hsa-miR-628-3p in PE development is still not elucidated, the aim of this study was to evaluate serum microRNA expression of hsa-miR-628-3p and hsa-miR-628-5p and their association with the preeclampsia development. A retrospective nested cohort case-control study was conducted. Serum samples from 16 pregnant women who developed preeclampsia (WWD-PE) during the follow-up period were selected and individually matched to that from 18 women in the cohort who had healthy pregnancies without complications (controls). The levels of hsa-miR-628-3p and hsa-miR-628-5p were measured in serum samples from study groups at 12, 16, and 20 weeks of gestation (WG) using TaqMan probes. Additionally serum levels were measured at the moment of diagnosis, in women with preeclampsia. Serum levels of hsa-miR-628-3p were higher than controls in WWD-PE at 12 WG (RQ = 7.7; P = 0.020), and of hsa-miR-628-5p at 20 WG (RQ = 3.4; P = 0.008). An increase in hsa-miR-628-3p serum levels at 12 WG (RQ = 12.01; P = 0.001) and of hsa-miR-628-5p at 20 WG (RQ = 2.95; P = 0.033) was also observed in women who developed mild preeclampsia, and severe preeclampsia, respectively. Serum hsa-miR-628-3p and hsa-miR-628-5p were differentially expressed between WWD-PE and controls, suggesting a participation of these miRNAs in the development of preeclampsia. Future studies are needed to validate hsa-miR628-3p and -5p as early predictors of preeclampsia.

Identifiants

pubmed: 31056146
pii: S2210-7789(18)30692-5
doi: 10.1016/j.preghy.2019.03.012
pii:
doi:

Substances chimiques

Biomarkers 0
MIRN628 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-125

Informations de copyright

Copyright © 2019 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Auteurs

Margarita L Martinez-Fierro (ML)

Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Campus UAZ siglo XXI, Carretera Zacatecas-Guadalajara Km 6, Ejido la Escondida, 98160 Zacatecas, Mexico. Electronic address: margaritamf@uaz.edu.mx.

Jose Gerardo Carrillo-Arriaga (JG)

Instituto Tecnologico de Estudios Superiores Monterrey, Campus Monterrey, Avenida Ignacio Morones Prieto 3000 Poniente, Los Doctores, 64710 Monterrey, Nuevo Leon, Mexico.

Martha Luevano (M)

Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.

Angel Lugo-Trampe (A)

Escuela de Medicina Humana, Campus IV, Universidad Autonoma de Chiapas, Tapachula, Chiapas 30700, Mexico.

Ivan Delgado-Enciso (I)

School of Medicine, University of Colima, Av. Universidad # 333, Colonia Las Viboras, 28040 Colima, Colima, Mexico.

Iram Pablo Rodriguez-Sanchez (IP)

Laboratorio de Fisiologia Molecular y Estructural, Facultad de Ciencias Biologicas, Universidad Autonoma de Nuevo Leon, Avenida Pedro de Alba s/n, Ciudad Universitaria, 66451 San Nicolás de los Garza, Nuevo Leon, Mexico.

Idalia Garza-Veloz (I)

Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Campus UAZ siglo XXI, Carretera Zacatecas-Guadalajara Km 6, Ejido la Escondida, 98160 Zacatecas, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH